These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 23506979)

  • 1. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.
    Rasmussen MH; Jensen NF; Tarpgaard LS; Qvortrup C; Rømer MU; Stenvang J; Hansen TP; Christensen LL; Lindebjerg J; Hansen F; Jensen BV; Hansen TF; Pfeiffer P; Brünner N; Ørntoft TF; Andersen CL
    Mol Oncol; 2013 Jun; 7(3):637-46. PubMed ID: 23506979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.
    Kjersem JB; Ikdahl T; Lingjaerde OC; Guren T; Tveit KM; Kure EH
    Mol Oncol; 2014 Feb; 8(1):59-67. PubMed ID: 24119443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
    Hu J; Cai G; Xu Y; Cai S
    Curr Mol Med; 2016; 16(1):70-82. PubMed ID: 26695693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
    Vasile E; Masi G; Fornaro L; Cupini S; Loupakis F; Bursi S; Petrini I; Di Donato S; Brunetti IM; Ricci S; Antonuzzo A; Chiara S; Amoroso D; Andreuccetti M; Falcone A
    Br J Cancer; 2009 Jun; 100(11):1720-4. PubMed ID: 19436300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
    Zhao J; Li W; Zhu D; Yu Q; Zhang Z; Sun M; Cai S; Zhang W
    Med Oncol; 2014 Jan; 31(1):802. PubMed ID: 24338217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
    Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D
    Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer.
    Yaman E; Uner A; Er O; Coskun U; Buyukberber S; Dikilitas M; Polat M; Yamac D; Kaya AO; Yildiz R; Ozturk B; Benekli M
    Med Oncol; 2007; 24(4):431-5. PubMed ID: 17917094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.
    Boisen MK; Dehlendorff C; Linnemann D; Nielsen BS; Larsen JS; Osterlind K; Nielsen SE; Tarpgaard LS; Qvortrup C; Pfeiffer P; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Høgdall EV; Jensen BV; Johansen JS
    PLoS One; 2014; 9(10):e109430. PubMed ID: 25329796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens.
    Marks EI; Matera R; Olszewski AJ; Yakirevich E; El-Deiry WS; Safran H; Carneiro BA
    Am J Clin Oncol; 2021 Feb; 44(2):68-73. PubMed ID: 33298767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
    Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
    Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
    J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
    Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
    Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.
    Argyriou AA; Velasco R; Briani C; Cavaletti G; Bruna J; Alberti P; Cacciavillani M; Lonardi S; Santos C; Cortinovis D; Cazzaniga M; Kalofonos HP
    Ann Oncol; 2012 Dec; 23(12):3116-3122. PubMed ID: 22865779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.
    Li YH; Luo HY; Wang FH; Wang ZQ; Qiu MZ; Shi YX; Xiang XJ; Chen XQ; He YJ; Xu RH
    J Cancer Res Clin Oncol; 2010 Apr; 136(4):503-10. PubMed ID: 19777259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
    Gerger A; El-Khoueiry A; Zhang W; Yang D; Singh H; Bohanes P; Ning Y; Winder T; Labonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; Absenger G; Lenz HJ
    Clin Cancer Res; 2011 Sep; 17(17):5783-92. PubMed ID: 21791631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
    Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
    J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.
    Zhou Y; Wan G; Spizzo R; Ivan C; Mathur R; Hu X; Ye X; Lu J; Fan F; Xia L; Calin GA; Ellis LM; Lu X
    Mol Oncol; 2014 Feb; 8(1):83-92. PubMed ID: 24145123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
    Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.